The Ensign Group, Inc.

The stock remains in a long-term corrective phase, trading below its 200-day average of 182.84 after a strong run toward the 52-week high. The shorter 50-day average near 168.16 sits close to price, signaling a consolidation regime rather than a fresh breakout or breakdown.

Street sentiment stays constructive: consensus is Buy with a 222.33 target, implying meaningful upside from current levels. Recent action has been mostly target raises from RBC, UBS, and Truist, while ratings have held steady rather than turning more cautious.

The setup leans favorable into earnings after Ensign has beaten EPS in 6 of the last 7 quarters. Next-year EPS is modeled at 8.33 versus 6.52 for 2025, so shareholders should watch whether the company can keep margin discipline while sustaining mid-teens growth.

Recent activity is mostly non-discretionary F-InKind filings, which are routine and not a strong trading signal. The only clear discretionary move is a director sale of 700 shares by Barry M. Smith, leaving the near-term pattern mildly negative but not heavy.

Profitability remains solid, with ROE at 16.92%, operating margin at 8.99%, and net margin at 6.89%. Growth is still healthy, with revenue up 18.4% year over year and earnings up 21.9%, while 2025 free cash flow reached $757.8 million and FCF yield was 7.68%.

Ensign’s appeal is its combination of steady earnings growth and cash generation in healthcare facilities, a segment where execution matters more than headline multiples. At 24.43x earnings, it trades at a premium to slower-growth healthcare operators, justified only if growth stays above plan.